Evernorth — the Cigna division that oversees ... that can help employers cap the monthly copays for two popular weight-loss drugs, Wegovy and Zepbound, at $200. The impact on the employers ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

Cigna’s (NYSE ... per month for patients using the weight-loss drugs - Wegovy from Novo Nordisk (NVO) and Eli Lilly’s (NYSE:LLY) Zepbound. The monthly copay for GLP-1 weight loss medicines ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

The Cigna Group (NYSE:CI)'s Evernorth division ... customers' monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. A healthcare team discussing strategies for patient ...

Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight ... help people with obesity access Zepbound." While Cigna would not discuss the actual ...